| Literature DB >> 31694579 |
Tae-Geun Gweon1, Sung Hoon Jung2,3, Sang Woo Kim1, Kang-Moon Lee1, Dae Young Cheung1, Bo-In Lee1, Hwang Choi1.
Abstract
BACKGROUND: Colonoscopy is associated with a risk of peritonitis in patients on peritoneal dialysis. However, no study has yet described the risk factors in play.Entities:
Keywords: Colonoscopy; Continuous ambulatory peritoneal dialysis; Peritoneal dialysis; Peritonitis
Mesh:
Year: 2019 PMID: 31694579 PMCID: PMC6836509 DOI: 10.1186/s12876-019-1081-2
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Baseline characteristics
| Characteristics | Peritonitis ( | No peritonitis ( |
|
|---|---|---|---|
| Male, n (%) | 5 (55.6) | 123 (54.2) | 1.000 |
| Age, years (± SD) | 52.6 (± 11.1) | 50.4 (± 16.7) | 0.061 |
| BMI, kg/m2 (± SD) | 24.3 (± 2.2) | 24.2 (± 3.3) | 0.796 |
| Etiology of ESRD | 1.000 | ||
| Diabetes, n (%) | 3 (33.3) | 85 (37.4) | |
| Non-diabetes, n (%) | 6 (66.7) | 142 (62.6) | |
| Duration of CAPD, months | 33.9 ± 25.5 | 51.4 ± 53.7 | 0.207 |
| Indication for colonoscopy | |||
| Screening, n (%) | 5 (55.6) | 137 (60.4) | 0.744 |
| Non-screening, n (%) | 4 (44.4) | 90 (39.6) | |
SD standard deviation, ESRD end stage renal disease, CAPD continuous ambulatory peritoneal dialysis
Factors related to colonoscopy
| Characteristics | Peritonitis (n = 9) | No peritonitis (n = 227) |
|
|---|---|---|---|
| Colonoscopist, n (%) | 0.505 | ||
| Expert, n (%) | 3 (33.3) | 118 (52.0) | |
| Trainee, n (%) | 6 (66.7) | 109 (48.0) | |
| Bowel preparation quality n (%) | |||
| Excellent or good | 9 (100) | 216 (95.2) | |
| Fair | 0 (0) | 11 (4.8) | |
| Colonoscopic procedure | 8 (88.9) | 115 (50.7) | 0.037 |
| Colon biopsy, n (%) | 2 (22.2) | 62 (27.3) | 1.000 |
| Polypectomy / EMR, n (%) | 6 (66.7) | 53 (23.4) | 0.009 |
| Use of prophylactic anbitiobitcs, n (%) | 0.067 | ||
| Yes | 0 (0) | 65 (28.6) | |
| No | 9 (100) | 162 (71.4) |
EMR endoscopic mucosal resection
Details of peritonitis
| Patient number | Sex | Age | Procedure | Culture | Treatment | Outcome |
|---|---|---|---|---|---|---|
| 1 | Female | 20–30 | Colon biopsy | No growth | Cefazolin + gentamycin | Recovered |
| 2 | Male | 30–40 | EMR | No growth | Cefazolin + gentamycin | Recovered |
| 3 | Male | 30–40 | Polypectomy |
| Vancomycin + ceftazidime | Recovered |
| 4 | Male | 40–50 | EMR |
| Cefamezine + tobramycin | Recovered |
| 5 | Female | 50–60 | EMR | No growth | Cefamezin + gentamycin | Recovered |
| 6 | Male | 50–60 | EMR |
| Cefamezin + gentamycin | Recovered |
| 7 | Male | 60–70 | Polypectomy |
| Cefazolin + gentamycin | Recovered |
| 8 | Female | 60–70 | Colon biopsy |
| Ceftazidime + metronidazole | Recovered |
| 9 | Female | 70–80 | No procedure |
| Cefazolin + gentamycin | Catheter removal |
EMR endoscopic mucosal resection